Does the media refer more to VTRS or AMRX?

In the previous week, Viatris had 3 more articles in the media than Amneal Pharmaceuticals. MarketBeat recorded 9 mentions for Viatris and 6 mentions for Amneal Pharmaceuticals. Viatris' average media sentiment score of 0.39 beat Amneal Pharmaceuticals' score of 0.31 indicating that Viatris is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Viatris 1 Very Positive mention(s) 3 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Amneal Pharmaceuticals 2 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to JAZZ or AMRX?

In the previous week, Jazz Pharmaceuticals had 10 more articles in the media than Amneal Pharmaceuticals. MarketBeat recorded 16 mentions for Jazz Pharmaceuticals and 6 mentions for Amneal Pharmaceuticals. Amneal Pharmaceuticals' average media sentiment score of 0.31 beat Jazz Pharmaceuticals' score of 0.29 indicating that Amneal Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Jazz Pharmaceuticals 4 Very Positive mention(s) 1 Positive mention(s) 6 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral Amneal Pharmaceuticals 2 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor NBIX or AMRX?

In the previous week, Neurocrine Biosciences had 1 more articles in the media than Amneal Pharmaceuticals. MarketBeat recorded 7 mentions for Neurocrine Biosciences and 6 mentions for Amneal Pharmaceuticals. Neurocrine Biosciences' average media sentiment score of 0.60 beat Amneal Pharmaceuticals' score of 0.31 indicating that Neurocrine Biosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Neurocrine Biosciences 2 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Amneal Pharmaceuticals 2 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to AMRX or CORT?

In the previous week, Corcept Therapeutics had 11 more articles in the media than Amneal Pharmaceuticals. MarketBeat recorded 17 mentions for Corcept Therapeutics and 6 mentions for Amneal Pharmaceuticals. Amneal Pharmaceuticals' average media sentiment score of 0.31 beat Corcept Therapeutics' score of 0.17 indicating that Amneal Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Amneal Pharmaceuticals 2 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Corcept Therapeutics 6 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer AMRX or ELAN?

In the previous week, Elanco Animal Health had 2 more articles in the media than Amneal Pharmaceuticals. MarketBeat recorded 8 mentions for Elanco Animal Health and 6 mentions for Amneal Pharmaceuticals. Amneal Pharmaceuticals' average media sentiment score of 0.31 beat Elanco Animal Health's score of 0.17 indicating that Amneal Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Amneal Pharmaceuticals 2 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Elanco Animal Health 1 Very Positive mention(s) 3 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Amneal Pharmaceuticals (AMRX) Competitors

$19.91 +0.26 (+1.32%)

Closing price 04:00 PM Eastern

Extended Trading

$20.00 +0.09 (+0.45%)

As of 04:21 PM Eastern

Compare

AMRX vs. VTRS, JAZZ, NBIX, CORT, and ELAN

Should you buy Amneal Pharmaceuticals stock or one of its competitors? Amneal Pharmaceuticals's main competitors and comparable companies include Viatris (VTRS), Jazz Pharmaceuticals (JAZZ), Neurocrine Biosciences (NBIX), Corcept Therapeutics (CORT), and Elanco Animal Health (ELAN). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Amneal Pharmaceuticals compare to Viatris?

Viatris (NASDAQ:VTRS) and Amneal Pharmaceuticals (NASDAQ:AMRX) are both healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, valuation, analyst recommendations, earnings, media sentiment, profitability, institutional ownership and dividends.

Viatris currently has a consensus price target of $20.50, indicating a potential upside of 17.55%. Amneal Pharmaceuticals has a consensus price target of $21.00, indicating a potential upside of 6.87%. Given Viatris' higher possible upside, research analysts plainly believe Viatris is more favorable than Amneal Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Viatris	1 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.56
Amneal Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.80

Amneal Pharmaceuticals has lower revenue, but higher earnings than Viatris. Viatris is trading at a lower price-to-earnings ratio than Amneal Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Viatris	$14.30B	1.40	-$3.51B	-$0.36	N/A
Amneal Pharmaceuticals	$3.12B	2.01	$72.06M	$0.49	40.10

Amneal Pharmaceuticals has a net margin of 5.05% compared to Viatris' net margin of -2.79%. Viatris' return on equity of 20.02% beat Amneal Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Viatris	-2.79%	20.02%	8.02%
Amneal Pharmaceuticals	5.05%	-584.46%	7.78%

79.9% of Viatris shares are held by institutional investors. Comparatively, 31.8% of Amneal Pharmaceuticals shares are held by institutional investors. 0.3% of Viatris shares are held by company insiders. Comparatively, 17.3% of Amneal Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Viatris had 3 more articles in the media than Amneal Pharmaceuticals. MarketBeat recorded 9 mentions for Viatris and 6 mentions for Amneal Pharmaceuticals. Viatris' average media sentiment score of 0.39 beat Amneal Pharmaceuticals' score of 0.31 indicating that Viatris is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Viatris	1 Very Positive mention(s)	3 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
Amneal Pharmaceuticals	2 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Viatris has a beta of 0.87, indicating that its stock price is 13% less volatile than the broader market. Comparatively, Amneal Pharmaceuticals has a beta of 1.22, indicating that its stock price is 22% more volatile than the broader market.

Summary

Amneal Pharmaceuticals beats Viatris on 9 of the 16 factors compared between the two stocks.

How does Amneal Pharmaceuticals compare to Jazz Pharmaceuticals?

Jazz Pharmaceuticals (NASDAQ:JAZZ) and Amneal Pharmaceuticals (NASDAQ:AMRX) are both healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, earnings, analyst recommendations, risk, media sentiment, profitability, valuation and institutional ownership.

Jazz Pharmaceuticals presently has a consensus target price of $291.25, indicating a potential upside of 30.93%. Amneal Pharmaceuticals has a consensus target price of $21.00, indicating a potential upside of 6.87%. Given Jazz Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Jazz Pharmaceuticals is more favorable than Amneal Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Jazz Pharmaceuticals	0 Sell rating(s)	1 Hold rating(s)	18 Buy rating(s)	1 Strong Buy rating(s)	3.00
Amneal Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.80

Amneal Pharmaceuticals has lower revenue, but higher earnings than Jazz Pharmaceuticals. Jazz Pharmaceuticals is trading at a lower price-to-earnings ratio than Amneal Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Jazz Pharmaceuticals	$4.27B	3.38	-$356.15M	$14.50	15.34
Amneal Pharmaceuticals	$3.12B	2.01	$72.06M	$0.49	40.10

89.1% of Jazz Pharmaceuticals shares are held by institutional investors. Comparatively, 31.8% of Amneal Pharmaceuticals shares are held by institutional investors. 4.1% of Jazz Pharmaceuticals shares are held by company insiders. Comparatively, 17.3% of Amneal Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Jazz Pharmaceuticals has a net margin of 20.45% compared to Amneal Pharmaceuticals' net margin of 5.05%. Jazz Pharmaceuticals' return on equity of 33.97% beat Amneal Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Jazz Pharmaceuticals	20.45%	33.97%	13.02%
Amneal Pharmaceuticals	5.05%	-584.46%	7.78%

Jazz Pharmaceuticals has a beta of 0.37, suggesting that its stock price is 63% less volatile than the broader market. Comparatively, Amneal Pharmaceuticals has a beta of 1.22, suggesting that its stock price is 22% more volatile than the broader market.

In the previous week, Jazz Pharmaceuticals had 10 more articles in the media than Amneal Pharmaceuticals. MarketBeat recorded 16 mentions for Jazz Pharmaceuticals and 6 mentions for Amneal Pharmaceuticals. Amneal Pharmaceuticals' average media sentiment score of 0.31 beat Jazz Pharmaceuticals' score of 0.29 indicating that Amneal Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Jazz Pharmaceuticals	4 Very Positive mention(s)	1 Positive mention(s)	6 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral
Amneal Pharmaceuticals	2 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Jazz Pharmaceuticals beats Amneal Pharmaceuticals on 12 of the 17 factors compared between the two stocks.

How does Amneal Pharmaceuticals compare to Neurocrine Biosciences?

Neurocrine Biosciences (NASDAQ:NBIX) and Amneal Pharmaceuticals (NASDAQ:AMRX) are both healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, earnings, institutional ownership, profitability, dividends, media sentiment, valuation and risk.

Neurocrine Biosciences presently has a consensus target price of $202.05, indicating a potential upside of 43.04%. Amneal Pharmaceuticals has a consensus target price of $21.00, indicating a potential upside of 6.87%. Given Neurocrine Biosciences' stronger consensus rating and higher possible upside, research analysts clearly believe Neurocrine Biosciences is more favorable than Amneal Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Neurocrine Biosciences	0 Sell rating(s)	5 Hold rating(s)	18 Buy rating(s)	1 Strong Buy rating(s)	2.83
Amneal Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.80

Neurocrine Biosciences has a net margin of 20.91% compared to Amneal Pharmaceuticals' net margin of 5.05%. Neurocrine Biosciences' return on equity of 22.43% beat Amneal Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Neurocrine Biosciences	20.91%	22.43%	15.64%
Amneal Pharmaceuticals	5.05%	-584.46%	7.78%

In the previous week, Neurocrine Biosciences had 1 more articles in the media than Amneal Pharmaceuticals. MarketBeat recorded 7 mentions for Neurocrine Biosciences and 6 mentions for Amneal Pharmaceuticals. Neurocrine Biosciences' average media sentiment score of 0.60 beat Amneal Pharmaceuticals' score of 0.31 indicating that Neurocrine Biosciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Neurocrine Biosciences	2 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Amneal Pharmaceuticals	2 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Neurocrine Biosciences has higher earnings, but lower revenue than Amneal Pharmaceuticals. Neurocrine Biosciences is trading at a lower price-to-earnings ratio than Amneal Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Neurocrine Biosciences	$2.86B	5.02	$478.60M	$6.82	20.71
Amneal Pharmaceuticals	$3.12B	2.01	$72.06M	$0.49	40.10

Neurocrine Biosciences has a beta of 0.4, indicating that its stock price is 60% less volatile than the broader market. Comparatively, Amneal Pharmaceuticals has a beta of 1.22, indicating that its stock price is 22% more volatile than the broader market.

92.6% of Neurocrine Biosciences shares are held by institutional investors. Comparatively, 31.8% of Amneal Pharmaceuticals shares are held by institutional investors. 4.6% of Neurocrine Biosciences shares are held by company insiders. Comparatively, 17.3% of Amneal Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Summary

Neurocrine Biosciences beats Amneal Pharmaceuticals on 13 of the 17 factors compared between the two stocks.

How does Amneal Pharmaceuticals compare to Corcept Therapeutics?

Amneal Pharmaceuticals (NASDAQ:AMRX) and Corcept Therapeutics (NASDAQ:CORT) are both healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, risk, earnings, profitability, institutional ownership, valuation, media sentiment and analyst recommendations.

Amneal Pharmaceuticals has a beta of 1.22, suggesting that its stock price is 22% more volatile than the broader market. Comparatively, Corcept Therapeutics has a beta of 0.4, suggesting that its stock price is 60% less volatile than the broader market.

Amneal Pharmaceuticals currently has a consensus price target of $21.00, suggesting a potential upside of 6.87%. Corcept Therapeutics has a consensus price target of $138.17, suggesting a potential upside of 16.56%. Given Corcept Therapeutics' higher probable upside, analysts clearly believe Corcept Therapeutics is more favorable than Amneal Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Amneal Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.80
Corcept Therapeutics	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.75

Corcept Therapeutics has lower revenue, but higher earnings than Amneal Pharmaceuticals. Amneal Pharmaceuticals is trading at a lower price-to-earnings ratio than Corcept Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Amneal Pharmaceuticals	$3.12B	2.01	$72.06M	$0.49	40.10
Corcept Therapeutics	$761.41M	16.83	$99.65M	$0.42	282.24

31.8% of Amneal Pharmaceuticals shares are owned by institutional investors. Comparatively, 93.6% of Corcept Therapeutics shares are owned by institutional investors. 17.3% of Amneal Pharmaceuticals shares are owned by insiders. Comparatively, 20.7% of Corcept Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Corcept Therapeutics has a net margin of 6.52% compared to Amneal Pharmaceuticals' net margin of 5.05%. Corcept Therapeutics' return on equity of 8.26% beat Amneal Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Amneal Pharmaceuticals	5.05%	-584.46%	7.78%
Corcept Therapeutics	6.52%	8.26%	6.45%

In the previous week, Corcept Therapeutics had 11 more articles in the media than Amneal Pharmaceuticals. MarketBeat recorded 17 mentions for Corcept Therapeutics and 6 mentions for Amneal Pharmaceuticals. Amneal Pharmaceuticals' average media sentiment score of 0.31 beat Corcept Therapeutics' score of 0.17 indicating that Amneal Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Amneal Pharmaceuticals	2 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Corcept Therapeutics	6 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Corcept Therapeutics beats Amneal Pharmaceuticals on 10 of the 17 factors compared between the two stocks.

How does Amneal Pharmaceuticals compare to Elanco Animal Health?

Amneal Pharmaceuticals (NASDAQ:AMRX) and Elanco Animal Health (NYSE:ELAN) are both healthcare companies, but which is the better business? We will compare the two companies based on the strength of their dividends, valuation, earnings, analyst recommendations, media sentiment, profitability, institutional ownership and risk.

Amneal Pharmaceuticals has higher earnings, but lower revenue than Elanco Animal Health. Elanco Animal Health is trading at a lower price-to-earnings ratio than Amneal Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Amneal Pharmaceuticals	$3.12B	2.01	$72.06M	$0.49	40.10
Elanco Animal Health	$4.72B	2.38	-$232M	-$0.41	N/A

Amneal Pharmaceuticals has a net margin of 5.05% compared to Elanco Animal Health's net margin of -3.96%. Elanco Animal Health's return on equity of 8.13% beat Amneal Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Amneal Pharmaceuticals	5.05%	-584.46%	7.78%
Elanco Animal Health	-3.96%	8.13%	3.99%

Amneal Pharmaceuticals has a beta of 1.22, meaning that its share price is 22% more volatile than the broader market. Comparatively, Elanco Animal Health has a beta of 1.7, meaning that its share price is 70% more volatile than the broader market.

31.8% of Amneal Pharmaceuticals shares are held by institutional investors. Comparatively, 97.5% of Elanco Animal Health shares are held by institutional investors. 17.3% of Amneal Pharmaceuticals shares are held by company insiders. Comparatively, 1.1% of Elanco Animal Health shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

In the previous week, Elanco Animal Health had 2 more articles in the media than Amneal Pharmaceuticals. MarketBeat recorded 8 mentions for Elanco Animal Health and 6 mentions for Amneal Pharmaceuticals. Amneal Pharmaceuticals' average media sentiment score of 0.31 beat Elanco Animal Health's score of 0.17 indicating that Amneal Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Amneal Pharmaceuticals	2 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Elanco Animal Health	1 Very Positive mention(s)	3 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Amneal Pharmaceuticals currently has a consensus target price of $21.00, indicating a potential upside of 6.87%. Elanco Animal Health has a consensus target price of $29.70, indicating a potential upside of 32.03%. Given Elanco Animal Health's higher probable upside, analysts plainly believe Elanco Animal Health is more favorable than Amneal Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Amneal Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.80
Elanco Animal Health	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.75

Summary

Amneal Pharmaceuticals beats Elanco Animal Health on 9 of the 17 factors compared between the two stocks.

Get Amneal Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding AMRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

AMRX vs. The Competition

Export

Metric	Amneal Pharmaceuticals	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$6.34B	$12.34B	$7.20B	$13.28B
Dividend Yield	N/A	2.65%	2.53%	16.36%
P/E Ratio	40.54	795.15	274.54	26.18
Price / Sales	2.03	835.80	585.60	81.39
Price / Cash	12.58	86.17	76.82	53.72
Price / Book	-86.33	10.74	11.21	6.33
Net Income	$72.06M	$2.84B	$3.50B	$381.90M
7 Day Performance	-2.19%	-0.70%	-0.68%	-1.27%
1 Month Performance	15.10%	-5.60%	-5.29%	-4.19%
1 Year Performance	92.95%	-5.07%	4.62%	-0.21%

Amneal Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
AMRX Amneal Pharmaceuticals	3.018 of 5 stars	$19.91 +1.3%	$21.00 +5.5%	+87.5%	$6.36B	$3.12B	40.63	8,500	Analyst Downgrade
VTRS Viatris	2.897 of 5 stars	$18.04 -1.3%	$19.50 +8.1%	+74.9%	$20.70B	$14.30B	N/A	30,000	Trending News
JAZZ Jazz Pharmaceuticals	4.2769 of 5 stars	$232.21 -2.5%	$289.37 +24.6%	+61.5%	$15.07B	$4.27B	16.01	2,890	Analyst Forecast Insider Trade
NBIX Neurocrine Biosciences	4.7991 of 5 stars	$137.89 -1.8%	$201.09 +45.8%	+1.6%	$14.00B	$2.86B	20.20	2,000	Analyst Forecast
CORT Corcept Therapeutics	3.4653 of 5 stars	$116.04 +0.4%	$138.17 +19.1%	+34.0%	$12.52B	$761.41M	275.67	730

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:AMRX) was last updated on 10/9/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Amneal Pharmaceuticals (AMRX) Competitors

AMRX vs. VTRS, JAZZ, NBIX, CORT, and ELAN

How does Amneal Pharmaceuticals compare to Viatris?

Summary

How does Amneal Pharmaceuticals compare to Jazz Pharmaceuticals?

Summary

How does Amneal Pharmaceuticals compare to Neurocrine Biosciences?

Summary

How does Amneal Pharmaceuticals compare to Corcept Therapeutics?

Summary

How does Amneal Pharmaceuticals compare to Elanco Animal Health?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AMRX vs. The Competition

Amneal Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Amneal Pharmaceuticals (AMRX) Competitors

AMRX vs. VTRS, JAZZ, NBIX, CORT, and ELAN

How does Amneal Pharmaceuticals compare to Viatris?

Do analysts prefer VTRS or AMRX?

Which has preferable earnings and valuation, VTRS or AMRX?

Is VTRS or AMRX more profitable?

Do insiders and institutionals have more ownership in VTRS or AMRX?

Does the media refer more to VTRS or AMRX?

Which has more risk and volatility, VTRS or AMRX?

Summary

How does Amneal Pharmaceuticals compare to Jazz Pharmaceuticals?

Do analysts recommend JAZZ or AMRX?

Which has higher valuation and earnings, JAZZ or AMRX?

Do institutionals & insiders have more ownership in JAZZ or AMRX?

Is JAZZ or AMRX more profitable?

Which has more volatility & risk, JAZZ or AMRX?

Does the media refer more to JAZZ or AMRX?

Summary

How does Amneal Pharmaceuticals compare to Neurocrine Biosciences?

Do analysts recommend NBIX or AMRX?

Is NBIX or AMRX more profitable?

Does the media favor NBIX or AMRX?

Which has better valuation and earnings, NBIX or AMRX?

Which has more risk and volatility, NBIX or AMRX?

Do institutionals and insiders believe in NBIX or AMRX?

Summary

How does Amneal Pharmaceuticals compare to Corcept Therapeutics?

Which has more risk & volatility, AMRX or CORT?

Do analysts recommend AMRX or CORT?

Which has stronger earnings & valuation, AMRX or CORT?

Do institutionals & insiders hold more shares of AMRX or CORT?

Is AMRX or CORT more profitable?

Does the media refer more to AMRX or CORT?

Summary

How does Amneal Pharmaceuticals compare to Elanco Animal Health?

Which has preferable valuation & earnings, AMRX or ELAN?

Is AMRX or ELAN more profitable?

Which has more volatility and risk, AMRX or ELAN?

Do institutionals & insiders have more ownership in AMRX or ELAN?

Does the media prefer AMRX or ELAN?

Do analysts prefer AMRX or ELAN?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AMRX vs. The Competition

Amneal Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools